Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients

Front Pharmacol. 2020 Jul 29:11:1156. doi: 10.3389/fphar.2020.01156. eCollection 2020.

¹ Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.

No abstract available

Keywords: COVID-19; Idasanutlin; MDM2; SARS-CoV-2; antiviral activity; new therapeutic approach; p53.